Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction
Abstract Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20–30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E)-stained pathological slides are used for routine diagnosis of cancer type, they may also con...
Saved in:
Main Authors: | Oz Kilim, Alex Olar, András Biricz, Lilla Madaras, Péter Pollner, Zoltán Szállási, Zsofia Sztupinszki, István Csabai |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-025-00808-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Circulating serum miRNAs predict response to platinum chemotherapy in high‐grade serous ovarian cancer
by: Kazuhiro Suzuki, et al.
Published: (2024-11-01) -
Macrophages Phenotype Regulated by IL-6 Are Associated with the Prognosis of Platinum-Resistant Serous Ovarian Cancer: Integrated Analysis of Clinical Trial and Omics
by: Xiaoqing Wu, et al.
Published: (2023-01-01) -
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
by: Elena Giudice, et al.
Published: (2024-03-01) -
Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
by: Luis Cordero Puentes, et al.
Published: (2018-05-01) -
Importance of serous intraepithelial ovarian tubal carcinomas in the occurrence of "high-grade" serous carcinomas and / or peritoneal serous carcinomas of unknown primary origin.
by: I. S. Shponka, et al.
Published: (2020-04-01)